Literature DB >> 18538174

Antitumor activity of vinflunine: effector pathways and potential for synergies.

Diane Braguer1, Jean-Marc Barret, Hayley McDaid, Anna Kruczynski.   

Abstract

Vinflunine is an innovative microtubule inhibitor of the vinca alkaloid class with distinct tubulin-binding properties. Preclinical evaluation of this novel microtubule inhibitor has shown superior antitumor activity against a broad spectrum of tumor types in vitro and in vivo, in comparison with other vinca alkaloids. The antitumor effect of vinflunine is largely attributable to its modulation of microtubule dynamics, and is mediated by its ability to induce apoptosis in target cells. At non-cytotoxic concentrations, vinflunine also exerts antiangiogenic and antivascular activity. The favorable preclinical profile of vinflunine, in addition to its synergism with a variety of other therapeutic modalities, justifies further clinical development of this compound.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538174     DOI: 10.1053/j.seminoncol.2008.01.011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   5.385


  11 in total

Review 1.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

2.  [Systemic therapy of metastatic bladder cancer.]

Authors:  M Retz; S C Schmid; M W Kramer; A S Merseburger
Journal:  Urologe A       Date:  2013-10-13       Impact factor: 0.639

3.  Stathmin potentiates vinflunine and inhibits Paclitaxel activity.

Authors:  Soazig Malesinski; Philipp O Tsvetkov; Anna Kruczynski; Vincent Peyrot; François Devred
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

4.  Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.

Authors:  Daniel Castellano; Javier Puente; Guillermo de Velasco; Isabel Chirivella; Pilar López-Criado; Nicolás Mohedano; Ovidio Fernández; Icíar García-Carbonero; María Belén González; Enrique Grande
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

Review 5.  Drug delivery systems and combination therapy by using vinca alkaloids.

Authors:  Chun-Ting Lee; Yen-Wei Huang; Chih-Hui Yang; Keng-Shiang Huang
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

6.  Vinflunine in the treatment of bladder cancer.

Authors:  Mark Bachner; Maria De Santis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 7.  Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.

Authors:  Armand Morel; Denis Talbot
Journal:  Open Access J Urol       Date:  2010-06-29

8.  From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.

Authors:  Gaetano Facchini; Chiara Della Pepa; Carla Cavaliere; Sabrina C Cecere; Marilena Di Napoli; Carmine D'Aniello; Anna Crispo; Gelsomina Iovane; Piera Maiolino; Teresa Tramontano; Raffaele Piscitelli; Salvatore Pisconti; Maurizio Montella; Massimiliano Berretta; Domenico Sorrentino; Sisto Perdonà; Sandro Pignata
Journal:  Front Pharmacol       Date:  2016-05-03       Impact factor: 5.810

Review 9.  Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.

Authors:  Steven C Brousell; Joseph J Fantony; Megan G Van Noord; Michael R Harrison; Brant A Inman
Journal:  Core Evid       Date:  2018-01-24

10.  Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).

Authors:  Rodolfo Passalacqua; Silvia Lazzarelli; Maddalena Donini; Rodolfo Montironi; Rosa Tambaro; Ugo De Giorgi; Sandro Pignata; Raffaella Palumbo; Giovanni Luca Ceresoli; Gianluca Del Conte; Giuseppe Tonini; Franco Morelli; Franco Nolè; Stefano Panni; Ermanno Rondini; Annalisa Guida; Paolo Andrea Zucali; Laura Doni; Elisa Iezzi; Caterina Caminiti
Journal:  BMC Cancer       Date:  2017-07-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.